Vitamin A

Clinical Summary

Vitamin A is an essential fat-soluble vitamin existing in two supplement-relevant forms: preformed retinoids (retinol, retinyl palmitate, retinyl acetate — from animal sources, direct bioactive) and provitamin A carotenoids (β-carotene, α-carotene, β-cryptoxanthin — from plants, enzymatically converted by BCO1/BCMO1 at variable efficiency). The active form, all-trans retinoic acid (ATRA), binds nuclear receptors (RAR/RXR) to regulate vision, epithelial differentiation, immune function, embryonic development, and iron mobilization.

The evidence base is paradoxical: vitamin A is a genuine life-saver in deficient populations (xerophthalmia, measles mortality, some preterm indications) and a curative pharmaceutical in acute promyelocytic leukemia (APL, as ATRA), but supplementation in well-nourished populations has repeatedly failed to show benefit and has documented harms (β-carotene + smoking → lung cancer; chronic preformed retinol → fracture risk + hepatotoxicity + teratogenicity). The 2024 EFSA opinion formally prioritized teratogenicity as the critical endpoint and tightened the upper intake level to 3,000 µg RE/day (~10,000 IU) for adults. The 2024 Phase 3 NeoVitaA trial (negative for BPD prevention) and Bjelakovic 2024 meta-analysis (no mortality benefit in individually randomized trials) further tighten the indication set.

Who benefits most: people with documented deficiency (serum retinol <0.7 µmol/L or symptoms — night blindness, Bitot's spots, xerosis), children in high-VAD regions per WHO protocol, APL patients (ATRA + arsenic trioxide, now chemotherapy-free), acne/photoaging patients (topical retinoids), retinitis pigmentosa under specialist protocol, and post-bariatric / cystic-fibrosis / chronic-cholestasis populations with fat malabsorption. Most well-nourished adults in industrialized countries get adequate vitamin A from diet; routine supplementation with preformed retinol carries more downside than upside unless deficiency is documented.

Indications & Evidence

Reading this table: Stars = evidence volume. Type = causal relationship strength. BH = Bradford Hill criteria met (/9). Safety = FAERS/trial signals for THIS specific indication.

Hard rule: Star rating cannot exceed the causal taxonomy ceiling for its Type.

Type codes: DC=Direct causation | PC=Probable | UCC=Unreplicated causal | BC=Biomarker correlation | SE=Surrogate endpoint | ME=Mechanistic extrapolation | AHE=Animal→human | OA=Observational | RC=Reverse causation | CF=Confounded | FA=Folk/anecdotal | NE=No evidence BH: 7-9=strong causal | 5-6=moderate | 3-4=weak | 1-2=speculative | 0=none Safety flags: -- No signals | MON Monitor (known AEs, manageable) | WARN FAERS or trial safety signal | AVOID Contraindicated for this specific indication

Star rating legend: 5/5 = multiple large RCTs + meta-analyses | 4/5 = several human RCTs | 3/5 = some human pilot/observational | 2/5 = animal/very limited human | 1/5 = none/debunked.

Prescribing

Dosing Table

Formulation Table

Condition-Specific Protocols

Measles with Suspected VAD (WHO Protocol)

Evidence: 5/5 | PMID 35294044

Phase 1 (Day 1): 200,000 IU PO (50,000 IU if <6 mo; 100,000 IU if 6-11 mo). Oil-based preparation preferred. Phase 2 (Day 2): Repeat same dose. Phase 3 (2-4 weeks later): Repeat single dose if clinical signs of VAD persist (night blindness, Bitot's spots, corneal involvement).

Expected Outcomes: ~87% reduction in measles mortality in children <2 years in deficient populations. Diarrhea duration reduction ~2 days. No benefit documented in well-nourished populations with low baseline VAD prevalence, but given negligible harm of a 2-dose high-dose regimen and high stakes, protocol is applied universally in measles per WHO.

Stop/Reassess Criteria: Transient vomiting within 48 hours is common (RR 1.97, Imdad 2022) and self-limited. Bulging fontanelle in infants <12 months → do not repeat. Signs of hypervitaminosis beyond 3 doses in a year → discontinue.

APL — ATRA + ATO (Chemotherapy-Free Protocol for Non-High-Risk)

Evidence: 5/5 | PMID 40825164 (APOLLO), 41906112 (meta-analysis)

Induction (Day 1-~28): ATRA 45 mg/m²/day PO divided BID + arsenic trioxide (ATO) 0.15 mg/kg/day IV. Add idarubicin for high-risk (WBC >10,000/μL at presentation). Prophylactic dexamethasone 10 mg BID for differentiation syndrome risk.

Consolidation: ATRA + ATO cycles per protocol (APL0406, APOLLO). Chemotherapy-free in non-high-risk.

Maintenance: Increasingly omitted for low-risk APL treated with ATRA+ATO.

Drug Interaction Timing: ATO with care if QT-prolonging drugs; ATRA interacts with CYP3A4 (avoid azoles during induction).

Expected Outcomes: >90% complete remission; >85% 5-year overall survival. Differentiation syndrome (fever, dyspnea, pleural/pericardial effusions) occurs in 15-25%; treat with dexamethasone.

Stop/Reassess: Differentiation syndrome severe → hold ATRA, continue dexamethasone. QT >500 ms → hold ATO.

Acne — Topical Tretinoin (Stepwise)

Evidence: 5/5 | PMID 38943431

Phase 1 (Weeks 1-4) — Retinization: Tretinoin 0.025% pea-sized amount to entire face, every 2-3 nights. Apply to dry skin 20 min after cleansing. Moisturizer sandwich method (moisturizer → wait → tretinoin → moisturizer) reduces irritation. Expect peeling, redness, "tret uglies" purge phase weeks 2-6. Use broad-spectrum SPF 30+ daily (non-negotiable).

Phase 2 (Weeks 4-12) — Therapeutic: Increase to every other night, then nightly as tolerated. Effect visible by week 8-12; peak by 6 months.

Phase 3 (6+ months) — Escalation (if incomplete response): Step up to 0.05% or 0.1%; or switch to tazarotene/trifarotene for more potency. Long-term nightly use sustains benefit.

Drug Interaction Timing: Avoid same-night benzoyl peroxide with tretinoin (stability concern, though newer data suggests overstated). Separate AHA/BHA nights from retinoid nights. Minimize waxing, microdermabrasion, chemical peels.

Expected Outcomes: Meaningful acne lesion reduction by week 8-12; photoaging/texture benefits plateau at 6-12 months.

Stop/Reassess: Barrier collapse (painful burning, fissuring) → pause 1-2 weeks, reintroduce at lower frequency. Pregnancy (topical systemic absorption low but category C) — most dermatology guidelines advise discontinuing in pregnancy despite minimal risk.

Retinitis Pigmentosa — Berson Protocol (Specialist-Managed)

Evidence: 3/5 | PMID NCT00000114

Induction & Maintenance: Retinyl palmitate 15,000 IU/day orally with fat. Add DHA 1,200 mg/day (per NCT00000116 and Berson studies). Add lutein 12 mg/day (NCT00346333).

Monitoring: Annual serum retinol (target 1.5-2.5 µmol/L), ALT/AST q6 months, DEXA scan at baseline + every 2 years, fasting lipid panel (carotenoid formulations), ophthalmologic evaluation including ERG and visual field q6-12 months.

Expected Outcomes: Slower rate of ERG amplitude decline. Does not restore lost vision.

Stop/Reassess: Liver enzyme elevation >3× ULN → hold. Pregnancy → discontinue (preformed retinol + RP risk must be weighed by retina specialist + OB). Bone loss on DEXA → reassess risk/benefit.

Safety

Interactions Table

Contraindications

• Pregnancy with preformed intake >10,000 IU/day — teratogenicity (craniofacial, CNS, cardiac defects; ~1 in 57 malformation rate at >10,000 IU early pregnancy per NEJM 1995)
• Active smoking or former smoker (≤5-10 years abstinent) + high-dose synthetic β-carotene (≥20 mg/day) — increased lung cancer (CARET/ATBC)
• Hepatic cirrhosis or active liver disease — impaired retinol metabolism, hepatotoxicity risk
• Chronic alcohol use >30 g/day + preformed vitamin A — hepatotoxicity synergy
• Hypervitaminosis A (acute or chronic) — discontinue all retinoid sources
• Concurrent systemic retinoid (isotretinoin/acitretin/bexarotene) — additive toxicity
• Severe renal failure with fluid restriction — vitamin A toxicity risk increases
• Hypercarotenemia (rare) — usually benign except in hypothyroid states
• Pregnancy + systemic retinoids (tretinoin, isotretinoin, acitretin, bexarotene) — Category X / known teratogens; iPLEDGE REMS mandates pregnancy prevention for isotretinoin

Adverse Effects (ranked by frequency from FAERS + clinical literature)

Oral preformed (Vitamin A / retinyl palmitate):

1. Nausea, vomiting (common at doses >25,000 IU acute)
2. Fatigue, headache (hypervitaminosis signal)
3. Arthralgia, bone pain (chronic hypervitaminosis; retinoid-class MSK effect)
4. Dry skin, peeling lips, telogen effluvium (hair shedding)
5. Pseudotumor cerebri / intracranial hypertension (case reports with chronic high-dose)
6. Hepatotoxicity (chronic >25,000 IU/day; stellate cell hyperplasia → perisinusoidal fibrosis → non-cirrhotic portal hypertension)
7. Teratogenicity (>10,000 IU preformed in early pregnancy)
8. Bone fragility / fracture risk (chronic >5,000 IU; osteoclast activation + osteoblast inhibition)
9. Hypercalcemia (classical hypervitaminosis component)
10. Bulging fontanelle in infants <12 months (transient, but protocol consideration)

Topical retinoids: Erythema, peeling, stinging, photosensitivity, hyperpigmentation rebound, contact dermatitis. Retinization phase (first 4-6 weeks) is universal.

Isotretinoin (most serious retinoid FAERS profile):

1. Dry lips/skin/eyes (>90%)
2. Elevated liver enzymes, hypertriglyceridemia
3. Depression, suicidal ideation (boxed warning — signal confirmed in FAERS: 5,727 depression + 2,126 suicidal ideation reports)
4. IBD (5,258 reports; meta-analyses inconclusive but signal persists in pharmacovigilance)
5. Teratogenicity (Category X, retinoic acid embryopathy — anotia, cleft lip/palate, cerebellar hypoplasia, Dandy-Walker, ASD)
6. Arthralgia, back pain, myalgia
7. Night vision decrease
8. Sexual dysfunction (ED, decreased libido, vulvovaginal dryness — TGA added to official label April 2025; 120+ RxISK enduring cases across 20+ countries)
9. Hyperostosis / DISH (chronic use)
10. Pseudotumor cerebri (especially with tetracyclines)

ATRA (APL): Differentiation syndrome (15-25% — fever, respiratory distress, effusions, weight gain, hypotension); treat with dexamethasone.

FAERS Signal Table

Reading FAERS data: Only rows where the compound is the suspect drug are clinically meaningful. Oral vitamin A FAERS signal is contaminated by parenteral multivitamin (INFUVITE) hospital reports, surgical noise, and polypharmacy confounding. Hypervitaminosis subset (21 reports with explicit MedDRA "Hypervitaminosis A") is the cleanest retinoid-toxicity signal and recapitulates classical clinical syndrome. Isotretinoin FAERS profile is the most severe retinoid safety profile and reflects systemic Rx exposure. Post-2024 shift in vitamin A FAERS toward T2DM / infusion-related reactions reflects INFUVITE IV use in hospitalized diabetics, not oral supplementation.

Monitoring Table

Special Populations

Hepatic Impairment

Renal Impairment

Pregnancy / Lactation / Reproductive Age

Synergies & Stacking

Individual Response Modifiers

Sex-Specific Considerations

Genetic Modifiers

Community & Anecdotal Evidence

Disclaimer: This section captures real-world user reports from online communities. None of this constitutes clinical evidence. N-sizes are approximate. Selection bias, placebo effect, and recall bias are inherent. Presented for completeness, not as medical guidance.

Dominant Sentiment

Mixed-to-cautious across ~hundreds of threads on r/Supplements, r/Nootropics, r/Biohackers. Strongly positive among ancestral-health and carnivore communities for liver consumption. Overwhelmingly positive for topical retinoids on r/SkincareAddiction, r/Tretinoin (tens of thousands of testimonials). Polarized for isotretinoin on r/Accutane vs r/AccutaneRecovery (large recovery community). Small but loud fringe movement (Grant Genereux / Garrett Smith "vitamin A is a toxin") on Low-Toxin Forum.

What Users Report

Community Dosing vs Clinical

Popular Stacks (Community)

Red Flags & Skepticism Notes

• MLM / affiliate-heavy brand ecosystem: Ancestral Supplements, Heart & Soil (Saladino), Liver Love, Perfect Supplements all operate aggressive affiliate programs. Most lack CoA transparency or third-party testing.
• Influencer concentration: Paul Saladino (Heart & Soil founder) publicly walked back carnivore ~2024 citing his own heart palpitations and sleep issues, yet his brand continues pushing the same protocol. Science-communicator critiques (Joe Schwarcz) flag the pattern.
• Weston Price Foundation / Green Pasture FCLO scandal (2015): WAPF's own VP commissioned independent lab tests finding Green Pasture Fermented Cod Liver Oil to be rancid, DNA-identified as Alaskan pollock (not cod), and low-D. WAPF disputed findings and lost that officer; lasting legitimacy hit. Alternatives: Rosita Extra Virgin, Nordic Naturals, Carlson's.
• Genereux / Smith "vitamin A toxicity" fringe: Unfalsifiable detox-worsening framework + monetized protocols + hair-mineral-analysis commerce. Pattern matches "scurvy of cranks." No peer-reviewed replication; ignores reversibility of deficiency-induced night blindness on vitamin A (well-documented).
• Astroturfing signals: Organ-meat brand forums show suspicious review concentration and affiliate-link overlap.
• Commercial bias: Most pro-high-dose retinol voices have direct product-sales relationships (Saladino, Smith, Genereux). Pro-moderate voices (Masterjohn) have educational monetization but not organ-meat SKUs.

Folk vs Clinical Reality Check

Community experience aligns with clinical data on: (a) topical retinoid efficacy for acne/photoaging, (b) isotretinoin efficacy + psychiatric/IBD/sexual-dysfunction signals (the "community knew first" pattern, now partially validated by TGA 2025 labeling), (c) hypervitaminosis symptomatology from chronic >25,000 IU (headache, hair shedding, bone pain, dry skin), (d) BCO1 conversion variability (replicated genetic data).

Community experience diverges from clinical data on: (a) Genereux "vitamin A toxin" thesis (contradicted by well-established deficiency syndromes), (b) Ray Peat 100,000 IU claims (unsupported by safety data; EFSA 2024 tightened UL), (c) pregnancy liver consumption safety (ancestral pushback against WHO/ACOG; resolution unlikely without prospective data), (d) beta-carotene conversion adequacy in vegetarians (low-converter genotype is common and real).

Most likely explanations for divergence: selection bias in self-report communities, publication bias in RCTs (less likely — harms often emerged from large trials), dosing extremes in folk protocols that no RCT has tested, and the placebo effect in subjective endpoints. Where ancestral orthodoxy contradicts evidence-based guidance (pregnancy liver, Ray Peat mega-dosing), the evidence-based position has stronger support.

Deep Dive: Mechanisms & Research

Classical Pathway

All-trans retinoic acid (ATRA) — the active metabolite — is a high-affinity ligand for nuclear retinoic acid receptors (RAR-α, β, γ) that heterodimerize with retinoid X receptors (RXR-α, β, γ). RAR/RXR heterodimers bind RARE (retinoic acid response elements) in gene promoters, regulating >500 genes governing cell cycle, differentiation, immune function, and development. 11-cis-retinal in photoreceptor outer segments binds opsin to form rhodopsin; photon absorption isomerizes it to all-trans-retinal, initiating visual cascade. RBP4 transports retinol from hepatic stores to peripheral tissues; zinc is required for RBP synthesis (zinc deficiency mimics VAD functionally even with adequate hepatic retinol stores).

Non-Classical Mechanisms (2024-2026)

• ACSL3 / ferroptosis / longevity (PMID 41909752, Luo 2026 Acta Pharm Sin B): Vitamin A and analogs modulate mono-unsaturated fatty acid (MUFA) metabolism via direct targeting of acyl-CoA synthetase long-chain 3 (ACSL3), improving ferroptosis resistance and aging phenotypes. First non-nuclear-receptor mechanism for vitamin A in longevity biology.
• Vitamin A5/X hypothesis (PMID 38904956, Bánáti 2024): 9-cis-13,14-dihydroretinol proposed as a distinct bioactive form signaling through RXR, potentially relevant to mental health and previously underdiagnosed deficiency states.
• RBP4 as adipokine (PMID 38520616, 41157128, 38637979): RBP4 drives insulin resistance independent of vitamin A transport; ATRA attenuates adipocyte-macrophage inflammation-induced insulin resistance in vitro. Emerging role as T2D biomarker.
• Immunometabolism / atherosclerosis (Blanco/Amengual 2024): β-carotene and vitamin A modulate macrophage polarization; atheroprotective signal from mechanism studies.
• Pancreatic stellate-cell anti-fibrotic signaling (PMID 38309676): Retinoic acid quiesces pancreatic stellate cells; therapeutic target for chronic pancreatitis.
• RAR signaling may be pathogenic in some contexts (JEM 2024 review): Metabolic syndrome, MASLD, and several solid cancers show retinoic acid pathway activation; pharmacologic RAR agonism is beneficial only in a narrow therapeutic window (APL, rare bone disorders, acne).

Clinical Trials (Selected from BioMCP / ClinicalTrials.gov — 1,645 vitamin A intervention trials total)

Regulatory Status

• FDA: Vitamin A migrated to dietary supplement / food regulation; ANDAs discontinued. INFUVITE Pediatric (NDA021265) is the only active Rx parenteral. Tretinoin oral (Vesanoid generics) FDA-approved for APL induction. Topical tretinoin, adapalene (OTC 2016 in US), trifarotene (2019) approved for acne. Isotretinoin under iPLEDGE REMS (2026-02-09 overhaul: home pregnancy testing permitted mid/post-treatment; 19-day lockout eliminated). Acitretin Category X (3-year post-therapy contraception per FDA). Bexarotene approved 1999 for CTCL.
• EMA: No centrally authorized vitamin A product; nationally authorized. Bexarotene (Targretin) centrally authorized 2001. Pregnancy Prevention Programmes (PPP) enforced nationally for isotretinoin/acitretin.
• EFSA 2024 (DOI 10.2903/j.efsa.2024.8814): Tightened UL to 3,000 µg RE/day adults; teratogenicity as critical endpoint; β-carotene UL not established; precautionary >15 mg/d synthetic β-carotene avoidance in smokers.
• EU Commission Regulation 2024/996: Caps cosmetic retinol at 0.05% RE body, 0.3% RE face/hand/rinse-off.
• WHO: Maintains universal high-dose pediatric VAS in VAD-endemic regions (100-200k IU q4-6mo); maintains measles 2-dose protocol; 2016 update no longer recommends universal neonatal VAS (post-NEOVITA 2015).
• Regulatory context: Vitamin A is off-patent and cannot support Rx commercial viability in well-nourished markets; its public-health role is global-south pediatric nutrition. Prescription retinoids (ATRA, isotretinoin, acitretin, bexarotene) remain commercially viable for their narrow indications.

Ataraxia Verdict (as of 2026-04-17)

Evidence Classification (Mode 5: Evidence Classifier)

Synthesized view in Indications & Evidence table above. Detailed rationale below.

Rationale: The compound spans the entire causal taxonomy depending on indication. Classical deficiency reversal is textbook DC (9/9 Bradford Hill). APL treatment as ATRA is a paradigm-defining DC with chemotherapy-free cure. Supplementation in well-nourished populations for preventive endpoints (cancer, mortality, URI) is mostly NE or low-BH OA/UCC. The bimodal distribution ("life-saver in deficiency, net-neutral-or-harmful in sufficiency") is the organizing fact.

Hype Check (Mode 1: Fallacy Radar)

• Appeal to nature / ancestral authority: "Humans ate liver for millennia so high-dose retinol is safe" ignores (a) episodic/seasonal liver consumption ≠ daily supplementation, (b) ancestral life expectancy did not test decades of chronic hypervitaminosis, (c) teratogenicity signal is dose-response, not absence/presence.
• Hasty generalization (animal→human): Preclinical ATRA ferroptosis / MUFA / anti-fibrotic mechanisms (PMID 41909752) are hypothesis-generating, not clinical indications. Don't extrapolate to oral supplementation.
• Appeal to authority (single researcher repeatedly cited): Ray Peat (who was not a clinician), Paul Saladino, Grant Genereux are frequently cited as authorities in their respective movements. Actual retinoid biology authorities are more cautious.
• Cherry-picking: Both sides do this. Anti-vitamin-A cranks ignore xerophthalmia reversibility; pro-megadose advocates ignore NeoVitaA, Bjelakovic, CARET, ATBC, EFSA 2024.
• Argument from popularity: "Millions take multivitamins with vitamin A" ≠ evidence of benefit; most multivitamin trials are negative for hard endpoints.
• Denying the antecedent: "Not FDA-approved for cancer prevention" is used to mean "therefore harmful" — but the evidence (CARET/ATBC) actually shows harm for a specific high-dose β-carotene + smoker combination, not all vitamin A supplementation.
• Straw-manning deficiency: "VAD is a third-world problem, irrelevant here" — ignores subclinical VAD in post-bariatric, cystic-fibrosis, chronic-cholestasis, alcohol-related liver disease, and extreme-diet populations.

Evidence Gaps

• No 2024-2026 adequately-powered RCT of oral vitamin A for adult all-cause mortality, cardiovascular endpoints, or cancer prevention in well-nourished populations.
• Pregnancy dosing controversy unresolved: no large prospective RCT of retinol >8,000 IU in pregnancy to replace the 1995 NEJM observational work that set the 10,000 IU ceiling.
• BCO1/BCMO1 conversion variability is well-documented genetically but clinical algorithm for deciding when to switch vegetarians/vegans to preformed retinol is not standardized.
• A5/X (9-cis-13,14-dihydroretinol) mental-health hypothesis needs clinical validation.
• Long-term topical tretinoin safety (30+ years) has limited prospective data despite massive use; systemic absorption is low but not zero.
• Isotretinoin post-treatment persistent sexual-dysfunction mechanism unknown; why recovery is incomplete in a subset is not understood.
• Interaction between preformed vitamin A and vitamin D in bone health is controversial; no RCT designed to address it.
• ATRA combinations in solid tumors (TNBC, sarcoma, pancreatic) are early-phase; efficacy data pending.
• Realgar-Indigo oral traditional arsenic for APL (PMID 39506905) is promising but not yet adopted outside China.
• Fine-grained individual-level VAD biomarker (gold-standard MRDR) is not field-practical.

Bias Flags (Mode 4: First Principles)

• Conflation of deficiency reversal with supplementation benefit: This is the single biggest error. "Vitamin A saves lives in children with xerophthalmia" does not mean "vitamin A supplementation benefits well-nourished adults." Both statements are true together.
• Conflation of dietary and supplemental β-carotene: Whole-food carotenoids (fruit, vegetables) show no lung cancer signal even in smokers; synthetic 20-30 mg β-carotene does. These are different exposures.
• RDA misapplied as "optimal": RDA is set to prevent deficiency in 97.5% of the population, not to optimize health. Conversely, supplementation above RDA is not automatically beneficial.
• Underappreciation of individual conversion variability: 45% of people have reduced BCO1 function. "Eat carrots for vitamin A" advice ignores this.
• Cui bono on safety narratives: Pharmaceutical companies profit from retinoid drugs (ATRA, isotretinoin, acitretin, bexarotene) — all priced significantly; supplement companies profit from cod liver oil and liver capsules — much cheaper market. Regulatory agencies have institutional interest in upholding ULs (risk aversion). Pharma incentive for vitamin-A fearmongering is weak because no major drug directly competes with vitamin A supplementation.
• Generalization of Accutane harms to all retinoids: Isotretinoin's psychiatric and IBD signals do not automatically extend to topical tretinoin (minimal systemic absorption) or dietary preformed vitamin A at RDA levels.
• Publication bias in folk evidence: Recovery subs (r/AccutaneRecovery) amplify harm signals; cleared-skin subs amplify benefit signals. Both are real but neither is representative.
• Ancestral-diet romanticization: Pre-industrial liver consumption was seasonal, not daily. Modern "nose-to-tail daily liver" is an innovation, not a return to tradition.

Manipulation Flags (Mode 2: Manipulation Shield)

• Industry marketing patterns detected:
  • Desiccated-liver brand ecosystem (Ancestral Supplements, Heart & Soil, Liver Love, Perfect Supplements, Carnivore Crisps) operates aggressive affiliate programs; influencer-aligned.
  • "Fermented cod liver oil" marketing pre-2015 Green Pasture scandal used ancestral/traditional framing that independent testing contradicted.
  • Cosmetic retinol marketing exploits the potency confusion (retinol vs retinal vs tretinoin) — charging prestige prices for formulations ~1/20 the potency of Rx generics.
  • Topical tretinoin generic is inexpensive ($15-40/mo); cosmetic retinol serums with 1/10 the potency often retail $60-150.
• Influencer economics:
  • Paul Saladino / Heart & Soil: founder walked back his own protocol in 2024 while brand continues selling it. Conflict of interest between personal practice evolution and brand product line.
  • Grant Genereux / Garrett Smith: low-A movement monetizes through hair-mineral analysis, detox protocols, supplement products. Classical "contrarian-with-SKU" pattern.
  • Ray Peat estate and forum communities have commercial connections to progesterone/retinol formulations.
• Counter-narrative manipulation:
  • Genereux/Smith movement weaponizes legitimate concerns (chronic hypervitaminosis from desiccated-liver overuse) into an unfalsifiable total-elimination framework.
  • Pharma "fearmongering" about retinol is weak — no major drug competes directly with vitamin A supplementation, so pharmaceutical cui bono for anti-retinol messaging is low. This differentiates vitamin A from compounds where pharma has strong incentives to discredit.
• Cui bono summary:
  • Benefit from popularization: supplement companies (cheap raw material, high markup), influencers (affiliate revenue), cosmetic brands (prestige markup on low-potency retinol).
  • Benefit from fear: fringe "toxicity" movement (monetized protocols), competing cosmetic brands (peptide/growth-factor alternatives).
  • Regulators: neutral; EFSA 2024 tightened based on teratogenicity without pharma pressure.
• Red team highlight (most concerning angle): The 45% BCO1 low-converter prevalence means "plant-based vitamin A adequacy" recommendations are misleading for nearly half the population — creating a systematic undertreated deficiency in vegetarians/vegans that is invisible on casual dietary assessment. This is the most clinically consequential manipulation angle because it affects routine dietary counseling.

Decision Support (Mode 3: Clarity Compass)

• Health utility score: 6/10 — compound-intrinsic. High utility for specific documented deficiency, APL, topical retinoid-responsive dermatologic conditions, and RP. Low utility for general supplementation in well-nourished adults. Genuine harm signal at chronic supraphysiologic doses. Cross-domain breadth is wide but most domains have null or harmful signals outside deficiency.
• Opportunity cost:
  • Financial: Low ($3-10/mo for cod liver oil or multivitamin-contained vitamin A); topical tretinoin $15-40/mo.
  • Complexity: Low for dietary sources + topical retinoid; moderate for decision-making around preformed vs β-carotene, pregnancy considerations, BCO1 genotype.
  • Attention: Moderate — requires self-awareness about accumulated dose across multivitamin + cod liver oil + fortified foods + organ meats.
• Hell Yes or No (Sivers): Not a Hell Yes for general supplementation. Hell Yes for (a) documented VAD, (b) APL (as ATRA under oncology care), (c) acne/photoaging (topical), (d) post-bariatric / CF / cholestasis, (e) RP under specialist care.
• Regret minimization: In 5 years: low regret about NOT supplementing oral preformed vitamin A if diet is adequate; potential regret about NOT using topical retinoids for skin aging; no regret about avoiding mega-dose (Peat/Saladino) protocols; low regret about including liver 1-2×/week as food.
• Verdict: CONDITIONAL
• Conditions warranting use:
  • Documented serum retinol <0.7 µmol/L or symptomatic VAD (night blindness, Bitot's spots, chronic xerosis)
  • Post-bariatric surgery, cystic fibrosis, chronic cholestasis, pancreatic insufficiency
  • APL diagnosis (ATRA under oncology)
  • Acne or significant photoaging (topical retinoids — high value)
  • Retinitis pigmentosa under retina specialist
  • Vegan/vegetarian with confirmed BCO1 low-converter genotype → preformed supplementation
  • Pregnancy planning with inadequate dietary access → β-carotene or prenatal with ≤4,000 IU preformed
  • Fat-malabsorption states

Bottom Line

Vitamin A is simultaneously a life-saving intervention (deficiency, measles, APL) and a supplement with real downside risk in well-nourished adults (fracture, teratogenicity, hepatotoxicity, smoker lung cancer for synthetic β-carotene). The population-wide answer is "get enough from food, use targeted supplementation only when indicated." The modern biohacker error is inferring from APL's dramatic curative effect that "more is better" for everyone — the evidence does not support this, and 2024 EFSA + NeoVitaA + Bjelakovic all tighten the indication window rather than widen it. Topical retinoids remain the highest-conviction intervention across this class for routine use. For oral supplementation, treat preformed vitamin A like a drug: know the dose, know the duration, know the indication, monitor the labs, and respect the teratogenicity boundary.

Practical Notes

Brands & Product Selection

Oral preformed retinol (if indicated):

• Thorne Vitamin A 10,000 IU (retinyl palmitate; third-party tested)
• Pure Encapsulations Vitamin A 10,000 IU
• NOW Vitamin A (budget option; reputable USP-grade)
• Avoid: Proprietary blends without clear IU per dose; "mega-dose" labels without medical indication.

Cod liver oil:

• Rosita Extra Virgin (non-fermented, third-party tested — safest choice)
• Nordic Naturals Arctic Cod Liver Oil
• Carlson's Norwegian Cod Liver Oil
• Avoid: Green Pasture fermented products (2015 rancidity/DNA scandal unresolved).

Desiccated liver:

• If pursuing this route, prefer real liver 50-100g 1-2×/week over capsules.
• Capsule brands with MLM/affiliate marketing patterns lack meaningful third-party testing. Paul Saladino (Heart & Soil) publicly moderated his own carnivore stance in 2024 while the brand continues marketing the original protocol.

Topical retinoids:

• Tretinoin: generic 0.025-0.1% gel/cream (Rx) is the gold standard. Cost: $15-40/month US.
• Adapalene: Differin 0.1% (OTC in US since 2016; Rx elsewhere) is a beginner-friendly alternative.
• Retinal (retinaldehyde): Medik8 Crystal Retinal is well-formulated. ~10× retinol potency with ~1/3 the irritation of tretinoin.
• Cosmetic retinol sweet spot: 0.3-1.0% serum (La Roche-Posay Redermic R, The Ordinary 1% in Squalane, CeraVe Resurfacing Retinol).

CoA requirements: For oral supplementation exceeding dietary, insist on third-party testing (USP, NSF, or independent lab) especially for cod liver oil (rancidity) and any desiccated-organ product.

Storage & Handling

• Oral vitamin A (retinyl palmitate capsules): Room temperature, dark bottle, desiccant. Shelf life 24-36 months sealed; once opened, use within 12 months.
• Cod liver oil: Refrigerate after opening. Rancidity is common — if it smells strongly fishy or sharp/rancid, discard. Fresh cod liver oil has a mild, not offensive, fish note.
• Topical tretinoin: Room temperature, dark tube. Photo-unstable — apply at night only. Shelf life 24 months sealed.
• Topical retinol/retinaldehyde: Prefer airtight, opaque pump packaging over jars. Oxidation-prone.

Palatability & Compliance

• Cod liver oil: unflavored is a deal-breaker for many; lemon or orange flavored versions dramatically improve compliance. Mix into smoothies if tolerated.
• Desiccated liver capsules: small capsules easier than chewables; take with meals to avoid nausea.
• Fresh liver: cooking methods (pâté, blended into ground beef, quickly seared) mask the flavor for those who struggle with the taste.
• Topical tretinoin: the #1 compliance determinant is tolerating the retinization phase. Use moisturizer sandwich method for first 4-8 weeks. Under-applying is better than abandoning the protocol. Habit stack with evening skincare routine.
• Vitamin A should always be taken with a fat-containing meal (minimum 5-10g fat) for absorption.

Exercise & Circadian Timing

• Topical retinoids: Apply at night only (photo-unstable; skin turnover higher overnight). Allow ≥20 min after cleansing for dry skin.
• Oral vitamin A: Morning or evening equivalent with fat-containing meal; timing does not materially affect outcome.
• Pre/post-workout: No specific relevance.

Reference Ranges (Expected Biomarker Changes)

Cost (Daily / Monthly for Therapeutic / Maintenance Dose)

• OTC retinyl palmitate 5,000-10,000 IU: ~$0.10-0.30/d; $3-10/mo
• Cod liver oil 1 tsp/d: ~$0.30-0.80/d; $10-25/mo
• Desiccated liver capsules (6/d): ~$1.00-2.00/d; $30-60/mo
• Fresh liver 100g weekly: ~$1.00-2.00/week; $5-10/mo
• Topical tretinoin (Rx generic): $0.50-1.30/d pro-rated; $15-40/mo
• Topical retinaldehyde (Medik8 or similar): ~$2-5/d; $60-150/mo
• Isotretinoin oral (generic): $50-100/month
• Bexarotene (CTCL): $5,000-10,000+/month

Cost-effectiveness favors diet-based vitamin A + targeted topical tretinoin for routine use; specialty products command premium pricing without proportional benefit for most indications.

What We Don't Know

• Whether the ACSL3 / ferroptosis / longevity mechanism (PMID 41909752) translates to clinical longevity benefit at any practical dose.
• The clinical significance of the A5/X (9-cis-13,14-dihydroretinol) pathway for mental health.
• Whether low-dose isotretinoin (10-20 mg/d) produces the same efficacy with meaningfully less psychiatric/IBD/sexual-dysfunction risk — observational data suggest yes but no head-to-head Phase 3.
• Mechanism for persistent post-isotretinoin sexual dysfunction in a subset of users; why recovery is incomplete.
• Whether preformed vitamin A genuinely undermines bone health in postmenopausal women independent of calcium/vitamin D status.
• Optimal pregnancy preformed-retinol ceiling — 10,000 IU is conservative but not experimentally derived.
• Whether topical tretinoin decades-long use has any systemic health signal (limited prospective data).
• How to operationalize BCO1 low-converter screening in routine dietary assessment.
• Whether Realgar-Indigo oral traditional arsenic (Chen 2025 PMID 39506905) for APL achieves equivalence outside Chinese populations.
• Which subpopulations benefit from vitamin A in COVID beyond the single Iranian pilot (PMID 36205099).
• Whether the universal pediatric VAS program in sub-Saharan Africa still provides mortality benefit in 2026 given changing measles/diarrhea epidemiology.

References

Systematic Reviews & Meta-Analyses

• Imdad A, et al. Cochrane Database Syst Rev 2022. Vitamin A supplementation for preventing morbidity and mortality in children 6 months to 5 years. PMID 35294044. Key: 47 trials, N=1,223,856; mortality RR 0.88 high certainty.
• Bjelakovic G, et al. BMJ Open 2024. Primary/secondary prevention vitamin A, TSA. PMID 38816049. Key: 120 RCTs, individually randomized RR 0.99 — challenges Cochrane.
• Cheng AL, et al. Cochrane Database Syst Rev 2024. Vitamin A for URI in children ≤7y. PMID 38738639. Key: low-certainty null.
• Gannon BM, et al. Cochrane Database Syst Rev 2025. VAD biomarkers review. PMID 40433851. Key: serum retinol + RBP imperfect; MRDR gold standard.
• McCauley ME, et al. Cochrane Database Syst Rev 2015. Pregnancy VAS. PMID 26503498. Key: no maternal/perinatal mortality effect; reduces night blindness.
• Sinopoli A, et al. 2024. Vitamins in COVID/Long-COVID meta-analysis. PMID 38732592. Key: vitamin A no definitive benefit.
• Shinde S, et al. 2025. LMIC pregnant/lactating MMN meta-analysis. PMID 40752545. Key: improved retinol, null infant growth.
• Meta-analysis of topical retinoids for acne. PMID 38943431.
• Meta-analysis ATRA+ATO vs ATRA+chemo APL. PMID 41906112.
• Umbrella meta: carotenoids for cancer prevention. PMID 38731692.
• Network meta: vitamins A-E for stroke. PMID 38291560.
• Anthracycline-free APL review. PMID 38507294.
• Vitamins in osteoporosis review. PMID 40376992.
• NHANES dietary carotenoids + fracture risk. PMID 40234943.
• Beta-carotene lung cancer meta-analysis (smokers). MDPI Nutrients 2022.

Landmark RCTs

• NeoVitaA (Meyer 2024, Phase 3). PMID 38643780. Key: NEGATIVE for BPD in ELBW preterms.
• Tan 2024-2025 red palm olein biscuit series (Malaysia food-based provitamin A). PMIDs 38240773, 40247111, 41125622.
• Li 2024 topical vitamin A palmitate ophthalmic gel for intraoperative ocular surface protection. PMID 38573375. POSITIVE.
• Zhou 2024 network meta for ROP prevention. PMID 37853107.
• Gutema 2024/2026 Ethiopia iron + vitamin A schoolchildren. PMIDs 37952928, 41291212.
• Zerback 2025 vegan multinutrient 4-month RCT. PMID 41417236.
• Lu 2024 carotenoid-enriched eggs RCT. PMID 38864191.
• Japanese FBMTG-APL2017 frontline ATRA+ATO. PMID 41564856.
• JPLSG AML-P13 pediatric APL ATO. PMID 40906031.
• Chen 2025 Realgar-Indigo oral traditional arsenic vs IV ATO in APL (multicenter China). PMID 39506905.
• CARET long-term follow-up (Gutiérrez-Torres 2024). PMID 38268471.
• NCT00000114 Berson RP vitamin A palmitate 15,000 IU/d (Phase 3 NEI).
• CARET (Omenn NEJM 1996) — seminal β-carotene + retinyl palmitate + smokers.
• ATBC (NEJM 1994) — β-carotene + lung cancer in smokers.
• NEOVITA (NEJM 2015) — neonatal VAS null.

Safety / Regulatory

• EFSA 2024 Scientific Opinion on UL preformed vitamin A. PMID 38846679. DOI 10.2903/j.efsa.2024.8814.
• Pestalardo L, et al. 2025. Chronic hepatic pathology from vitamin A excess. PMID 40901583.
• Lerner UH, et al. Front Endocrinol 2024. Retinoid-bone review. PMID 38711977.
• Xiang J, et al. 2025 Mendelian randomization — retinol and BMD. PMID 40240651.
• Phiri 2026. Calcium attenuates vitamin A-induced BMD loss (swine). PMID 41759827.
• Hajaj K, et al. 2024. Pseudotumor cerebri from chronic hypervitaminosis A. PMID 38817456.
• Bates P, et al. 2024. Integrated risk assessment β-carotene whole food. PMID 39522798.
• Rothman KJ, et al. NEJM 1995. Teratogenicity of high vitamin A intake during pregnancy.
• FDA iPLEDGE REMS documentation (2026 overhaul).
• EU Commission Regulation 2024/996 (cosmetic retinol caps).
• WHO 2011 Vitamin A Supplementation guidelines (infants 1-5 months, 6-59 months, neonates).
• IOM 2001 DRIs chapter on Vitamin A.

Mechanism

• Luo Y, et al. Acta Pharm Sin B 2026. Vitamin A + analogs modulate MUFA via ACSL3. PMID 41909752.
• Bánáti D. 2024. Vitamin A5/X (9-cis-13,14-dihydroretinol) hypothesis. PMID 38904956.
• Kumar S, et al. 2025. MD + stochastic modelling of RXR-RAR heterodimer kinetics. PMID 41163170.
• Belyaeva OV, et al. 2024. Synthetic rexinoid RXR activation → intracellular ATRA synthesis. PMID 38557762.
• Corcoran J, Mey J. 2024. CNS retinoic acid signaling in neuroregeneration (editorial + collection). PMID 39558937.
• Sun X, et al. 2024. Retinoic acid anti-fibrotic in pancreatic stellate cells. PMID 38309676.
• Fan J, Hu Y. 2024. RBP4 adipokine driving insulin resistance. PMID 38520616.
• Baek J, Kim J. 2025. ATRA attenuates adipocyte-macrophage inflammation (Korea). PMID 41157128.
• Blanco CE, Amengual J. 2024. β-carotene + vitamin A atheroprotection via macrophage polarization (immunometabolism review).
• Wu et al. 2024 RBP4 rs3758539 meta-analysis (Taiwan). PMID 38637979.

Pharmacogenomics

• Jamnik J, et al. 2024. GWAS plasma carotenoid variants (BCO1/PKD1L2 region). PMID 39603182.
• Han C, et al. 2024 (medRxiv). Ancestry-stratified carotenoid variant effects. PMID 39763521.
• Shen J, et al. 2025. Mitochondrial BCO2 governs macular pigment. PMID 39978586.
• Qu L, et al. 2026. Environmental CYP26A1 modulation (nanoplastics). PMID 41621212.
• BCO1 R267S/A379V original identification. PMID 22113863.

Disease-Specific / Clinical Reviews

• Esposito E, Amory JK, Kang S. J Exp Med 2024. Retinoid pathway pathogenic in metabolic syndrome, MASLD, solid cancers review.
• APOLLO trial (APL ATRA+ATO chemotherapy-free). PMID 40825164.
• FAERS hypervitaminosis A case cluster (21 reports, 100% hypercalcemia signal).
• Gigante PR et al. 2024 retinoid hypothesis CDH review. PMID 37990078.
• Kaeden M, et al. 2024 RBP4-CKD association. PMID 39698033.
• VAD and urinary tract developmental abnormalities. PMID 39397601.
• Post-isotretinoin sexual-dysfunction narrative review; RxISK enduring-case compilation; TGA Australia April 2025 label addition.

East Asian / Food-Based

• Golden Rice Philippines commercial cultivation 2023 (policy/regulatory; no 2024-2026 indexed efficacy RCT yet).
• Kafi 2007 / Kikuchi 2010 Japanese topical retinol 0.075% split-face photoaging RCT.
• ChiCTR-ROC-14005442, ChiCTR-OPC-17013502, ChiCTR-OOC-16008846 (Chinese pediatric VAS / ASD / complementary-food registries).

Classical Historical References

• Vitamin A palmitate 15,000 IU/d for retinitis pigmentosa — Berson EL, Arch Ophthalmol 1993.
• Isotretinoin for severe nodular acne — Peck GL, et al. N Engl J Med 1979.
• ATRA + APL — Huang ME, et al. Blood 1988.
• Night blindness reversibility in VAD — Sommer A et al.